Biopharma Goes 3 For 3 In Presidential Debates
Executive Summary
The Presidential debates are over, and the biopharmaceutical industry has to be counted among the winners, simply because there was no substantive discussion of high drug prices as an issue. That may not mean much come 2017 – but at least the industry’s reputation hasn’t been further damaged during the highest profile phase of the national campaign.
You may also be interested in...
Clinton Transition Co-Chair Tanden Offers Themes For A Drug Pricing Bill In 2017
FAIR Drug Pricing Act, CAP proposal and Collins bill include viable legislative movers for next administration. CMS Acting Administrator Slavitt signals that Part B demo will move forward based on CBO score.
Drug Prices Enter Presidential Debate – Not That Anyone Noticed
Second Presidential debate included the first direct discussion of health care issues by the candidates, and the first reference to prescription drug costs. The passing reference was, to put it mildly, overshadowed by other topics.
Big Pharma’s Big Debate Win
Sometimes silence is golden. The first Presidential debate had lots of noise – but no discussion of health care, much less drug pricing. And, as an added bonus, both candidates agreed that tax repatriation is a good idea.